1. The Clinical and Economic Potential of Cyclosporin Drug Interactions

   • Jill E. Martin
   • A. Jamal Daoud
   • M. Roy First

   Review Article 11 October 2012 Pages: 317 - 337

2. Methodological Hurdles in Conducting Pharmacoeconomic Analyses

   • J. Douglas Rizzo
   • Neil R. Powe

   Review Article 11 October 2012 Pages: 339 - 355

3. Recent Advances in the Methods of Cost-Benefit Analysis in Healthcare

   • Emma McIntosh
   • Cam Donaldson
   • Mandy Ryan

   Review Article 11 October 2012 Pages: 357 - 367

4. Utility Scores for Chronic Conditions in a Community-Dwelling Population

   • Nicole Mittmann
   • Kostas Trakas
   • Barbara A. Liu

   Original Research Article 11 October 2012 Pages: 369 - 376

5. Treatment of Locally Advanced Pancreatic Carcinoma in Sweden

   • Gunnel Ragnarson-Tennvall
   • Nils Wilking

   Original Research Article 11 October 2012 Pages: 377 - 384

6. Applying Epidemiology-Based Outcomes Research to Clinical Decision-Making

   • Edward C. Y. Wang
   • Thaddeus H. Grasela
   • Cynthia A. Walawander

   Original Research Article 11 October 2012 Pages: 385 - 393

7. Cost Analysis of the Treatment of Severe Spinal Spasticity With a Continuous Intrathecal Baclofen Infusion System

   • Theo Postma
   • Dettie Oenema
   • Berry J. Middel

   Original Research Article 11 October 2012 Pages: 395 - 404

8. Vinorelbine in Advanced Non–Small Cell Lung Cancer

   • Allan J. Coukell
   • Stuart Noble
   • Diana Faulds

   Adis Pharmacoeconomic Drug Evaluation 11 October 2012 Pages: 405 - 417